GILD

Peers: GSK MRK BMY AMGN ABBV AZN LLY REGN VRTX BIIB

| Held by: VTI VOO QQQ IVV SPY VTV XLV VIG IBB QQQM

Index	NDX, S&P 500
Market Cap	192.50B
Enterprise Value	213.78B
Income	-3.24B
Sales	30.54B
Book/sh	9.53
Cash/sh	3.94
Dividend Est.	3.30 (2.12%)
Dividend TTM	3.25 (2.09%)
Dividend Ex-Date	Sep 15, 2026
Dividend Gr. 3/5Y	2.67% 3.04%
Payout	46.60%
Employees	17000
IPO	Jan 22, 1992

P/E	-
Forward P/E	15.54
PEG	1.59
P/S	6.30
P/B	16.29
P/C	39.43
P/FCF	14.87
EV/EBITDA	14.58
EV/Sales	7.00
Quick Ratio	1.09
Current Ratio	1.27
Debt/Eq	2.22
LT Debt/Eq	2.01
Option/Short	Yes / Yes

EPS (ttm)	-2.66
EPS next Y	9.99
EPS next Q	2.18
EPS this Y	-105.05%
EPS next Y	2528.34%
EPS next 5Y	9.77%
EPS past 3/5Y	23.06% 133.64%
Sales past 3/5Y	2.83% 3.63%
EPS Y/Y TTM	-151.43%
Sales Y/Y TTM	6.05%
EPS Q/Q	-640.66%
Sales Q/Q	10.73%
Earnings	Oct 29 AMC
EPS/Sales Surpr.	6.85% 5.47%

Insider Own	0.16%
Insider Trans	-8.91%
Inst Own	92.72%
Inst Trans	0.12%
ROA	-6.17%
ROE	-20.57%
ROIC	-9.09%
Gross Margin	79.66%
Oper. Margin	39.05%
Profit Margin	-10.61%
SMA20	3.34%
SMA50	5.13%
SMA200	12.22%
Trades

Shs Outstand	1.24B
Shs Float	1.24B
Short Float	1.76%
Short Ratio	3.61
Short Interest	21.83M
52W High	160.51 -3.28%
52W Low	114.02 36.16%
Volatility	2.77% 2.45%
ATR (14)	3.88
RSI (14)	59.86
Beta	0.39
Rel Volume	0.65
Avg Volume	6.05M
Volume	2,213,173

Perf Week	4.96%
Perf Month	3.12%
Perf Quarter	19.11%
Perf Half Y	16.48%
Perf YTD	26.49%
Perf Year	26.11%
Perf 3Y	99.55%
Perf 5Y	132.20%
Perf 10Y	108.92%
Recom	1.63
Target Price	161.32
Prev Close	153.07
Price	155.25
Change %	1.42%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-21-26	Downgrade	Leerink Partners	Outperform → Market Perform	$127
Jul-06-26	Upgrade	HSBC Securities	Hold → Buy	$155
May-20-26	Upgrade	Maxim Group	Hold → Buy	$165
Mar-10-26	Initiated	Jefferies	Buy	$180
Feb-20-26	Initiated	Barclays	Equal Weight	$155
Feb-11-26	Reiterated	Needham	Buy	$140 → $170
Jan-07-26	Resumed	UBS	Buy	$145
Nov-24-25	Resumed	Truist	Buy	$140
Nov-13-25	Initiated	Scotiabank	Sector Outperform	$140
Aug-19-25	Upgrade	Daiwa Securities	Neutral → Outperform	$128
Aug-08-25	Upgrade	Truist	Hold → Buy	$127
Jul-25-25	Upgrade	Needham	Hold → Buy	$133
Apr-22-25	Resumed	Cantor Fitzgerald	Overweight	$125
Mar-04-25	Reiterated	Oppenheimer	Outperform	$115 → $132
Feb-18-25	Upgrade	Deutsche Bank	Hold → Buy	$120
Feb-13-25	Upgrade	DZ Bank	Hold → Buy	$108
Jan-10-25	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$87 → $113
Dec-10-24	Resumed	BofA Securities	Buy	$109
Nov-15-24	Initiated	Wolfe Research	Outperform	$110
Nov-14-24	Initiated	Citigroup	Buy	$125

Show Previous Ratings

Oct-19-26 08:00AM	Gilead to Present New Data Across HIV and Emerging Antiviral Research at IDWeek 2026 (Business Wire)
Oct-16-26 08:37PM	Gileads HIV Prevention Business Just Topped $1 Billion A Quarter. What Comes Next? (Trefis)
07:57PM	Stocktwits Biotech Dealmaker: Gilead, AstraZeneca And Roche Chase Pipeline Expansion Over Buyouts (Stocktwits)
Oct-15-26 04:05PM	Gilead Sciences to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026 (Business Wire)
03:36PM	Healthcare Stocks Are on a Tear. Gilead and AbbVie Are Heading for Record Highs. (Barrons.com)
02:25PM	Loading…
02:25PM	Big pharma stocks near all-time highs as tech selloff pushes investors toward safer bets (MarketWatch)
10:30AM	Gilead and Vir forge $1.9bn pact to develop next-gen T-cell engagers (Pharmaceutical Technology)
Oct-14-26 09:31AM	J&J earnings set negative tone; Shkreli vs. the FTC (BioPharma Dive)
Oct-09-26 08:47PM	Why Is Everyone Ignoring Gilead Stock's High Cash Yield? (Trefis)
Oct-07-26 07:14PM	Is Exelixis Stock Engineered To Make You Money? (Trefis)
09:48AM	Former Gilead and Amgen Commercial Leader Laura Hamill Just Joined Entera (NASDAQ: ENTX) (FinanceWire)
06:12AM	Gilead Sciences signs five-year DevOps agreement with Cognizant (Pharmaceutical Business Review)
Oct-01-26 10:25PM	More Upside Awaits for Gilead Sciences Stock. Stay Invested. (Barrons.com)
Sep-21-26 08:20AM	Novo Nordisk Stock Drops 5.6% as 2030 Goals Match Peers (GuruFocus.com)
Sep-16-26 09:46AM	Gilead Expands Lenacapavir Licensing Agreements to Include Once-Yearly HIV Prevention Formulation (InvestorsHub)
11:10AM	Loading…
Sep-15-26 11:10AM	Gilead and PAHO Announce Milestone Partnership to Accelerate Access to Twice-Yearly Lenacapavir for HIV Prevention Across Latin America and the Caribbean (Business Wire)
07:01AM	Gilead Sciences Inc's Dividend Analysis (GuruFocus.com)
Sep-09-26 06:59AM	Gilead launches research facility in US for new medicine development (Pharmaceutical Technology)
Sep-08-26 01:00PM	Gilead Opens State-of-the-Art Research Center to Advance the Next Generation of Medicines (Business Wire)
Sep-04-26 05:10AM	Gileads growing HIV franchise; cell therapy licensing deals plummet (Pharma Voice)
Sep-01-26 04:39PM	Top Research Reports for Toyota Motor, CrowdStrike & Welltower (Zacks)
Aug-31-26 11:39AM	Cocrystal Pharma: The Strategic Reset Investors May Be Missing (Exec Edge)
Aug-28-26 07:59AM	Moderna raises $2.6B to support cancer work; FDA clears updated COVID vaccines (BioPharma Dive)
Aug-27-26 05:47PM	U.S. FDA Approves Gilead's Bixlenvo, a New Once-Daily Single Tablet Option for Virologically Suppressed Adults With HIV, Including Those on Complex Regimens (Business Wire)
Aug-26-26 04:05PM	Gilead Sciences to Present at Upcoming Third Quarter 2026 Investor Conferences (Business Wire)
02:20PM	ITOC Stockholders Have Rights - If You Lost Money Investing in iTonic Holdings Ltd. Contact Robbins LLP for Information About Recovering Your Losses (Business Wire)
09:29AM	Vivace Therapeutics names new CEO as it prepares Phase 3 trial for mesothelioma drug (Proactive)
Aug-25-26 03:30PM	Eli Lilly Is Pulling Away From the Rest of Healthcare (GuruFocus.com)
Aug-24-26 04:04PM	GILD Stock Garners Retail Attention On Trodelvy EU Approval Ahead Of August 27 HIV FDA Verdict (Stocktwits)
02:36PM	Exelixis Owners Keep Getting A Bigger Slice Of A Company In Transition (Trefis)
06:31AM	Loading…
06:31AM	European Commission Expands Role of Gilead's Trodelvy in First-Line Metastatic Triple-Negative Breast Cancer Across PD-L1 Status (Business Wire)
Aug-19-26 10:44AM	Biotech Stocks Are Booming. What This Top Fund Is Buying Now. (Barrons.com)
06:30AM	HEALWELL AI's DARWEN(TM) AI Platform Nominated for 2026 International Prix Galien, the Global "Best of the Best" in Life Sciences Innovation (TMX Newsfile)
Aug-14-26 06:15PM	Did You Lose Money Investing in iTonic Holdings Ltd.? Robbins LLP Urges Investors With Significant Losses to Contact the Firm for Information About Their Rights Against ITOC (PR Newswire)
01:34PM	Gilead wins appeals court ruling against overseas drug imports (Quartz)
Aug-13-26 11:01AM	Your prescription drugs shouldn't cost more than your mortgage. Inside the broken math that got us here. (MarketWatch)
Aug-10-26 01:01AM	GILD- An Attractive Biotech Stock with Solid Base Revenue Growth (MoneyShow)
Aug-07-26 11:39AM	What Insmed Stock's Premium Is Actually Buying (Trefis)
Aug-06-26 07:04AM	MSD and Gilead scrap Phase III Trodelvy-Keytruda study on lacklustre interim data (Clinical Trials Arena)
Aug-05-26 03:01PM	Compass Pathways PLC (CMPS) (Q2 2026) Earnings Call Highlights: Strong Cash Position and NDA ... (GuruFocus.com)
07:00AM	Earnings roundup: Gileads uncertain future, Pfizers crossroads and Mercks PCSK9 launch (BioPharma Dive)
01:06AM	Gilead Sciences Inc (GILD) (Q2 2026) Earnings Call Highlights: PrEP Sales Double to $1B, HIV ... (GuruFocus.com)
Aug-04-26 09:41PM	CORRECTING and REPLACING Gilead Sciences Announces Second Quarter 2026 Financial Results (Business Wire)
04:31PM	Gilead Sciences Swings to Loss on R&D Costs as HIV-Drug Sales Lift Revenue (The Wall Street Journal)
04:12PM	Why Gilead's High-Profile HIV Drug Might Have To Play Catch-Up (Investor's Business Daily)
04:12PM	Gilead Posts a Loss on Acquisitions but Revenue Tells a Bigger Story (Barrons.com)
04:08PM	Gilead: Q2 Earnings Snapshot (Associated Press)
04:01PM	Gilead Sciences Announces Second Quarter 2026 Financial Results (Business Wire)
Jul-31-26 03:29PM	Is The Recent Pullback In Alnylam Stock An Opportunity Or A Trap? (Trefis)
Jul-29-26 05:49AM	BMS and Gilead rule in the CAR-T space. Off-the-shelf developers arent trying to change that. (Pharma Voice)
Jul-28-26 05:48AM	Kalshi is expanding online betting in drug R&D unless detractors can stop it (Pharma Voice)
Jul-24-26 06:26AM	CHMP Recommends Gilead's Trodelvy Plus Keytruda in PD-(L)1-Positive First-Line Metastatic Triple-Negative Breast Cancer (Business Wire)
Jul-22-26 05:33AM	Summit counters PD-1/VEGF skeptics; Celldex drug fails skin disease study (BioPharma Dive)
Jul-21-26 04:05PM	Gilead Sciences to Release Second Quarter 2026 Financial Results on Tuesday, August 4, 2026 (Business Wire)
10:00AM	Gilead to Present New HIV Research at AIDS 2026 Across Prevention, Treatment and Cure (Business Wire)
Jul-17-26 12:55PM	Gilead Leads The Battle Vs. HIV. But Rivals Are On The Move. (Investor's Business Daily)
Jul-16-26 01:00PM	Kalshi Allows Betting On Clinical Trials And FDA Drug Decisions (CryptoProwl)
08:00AM	Kalshi Will Offer Sports-Style Betting on Drug Trial Results (Bloomberg)
Jul-13-26 01:37PM	Own Regeneron For Biotech Growth? Incyte Is Making Its Case. (Trefis)
Jul-10-26 04:30PM	Gilead Sciences Inc. stock underperforms Friday when compared to competitors (MarketWatch)
Jul-07-26 04:30PM	Gilead Sciences Inc. stock outperforms competitors on strong trading day (MarketWatch) +5.21%
Jul-06-26 12:00PM	The Cancer Therapy Strategy VERAXA Is Betting the Company On (Exec Edge)
09:47AM	Okta upgraded, Datadog downgraded: Wall Street's top analyst calls (The Fly)
Jun-30-26 04:10PM	Imviva Biotech Granted FDA IDE Authorization for Cancer Treatment Trial (Exec Edge)
Jun-24-26 04:29PM	U.S. FDA Approves Trodelvy for First-Line Treatment of Metastatic Triple-Negative Breast Cancer (Business Wire)
02:15PM	VERAXA Biotech Expands R&D Hub in Heidelberg as Programs Advance Towards Clinical Development (Exec Edge)
Jun-23-26 08:20AM	Should You Buy Or Sell AbbVie Stock At $230? (Trefis)
07:45AM	European Commission Approves Trodelvy as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer Patients Not Candidates for PD-(l)1 Inhibitors (Business Wire)
Jun-22-26 11:40AM	Prolium Bioscience Sclerosis, Lupus Treatment Studies Advancing (Exec Edge)
Jun-18-26 10:34AM	VERAXA Unveils Cancer Therapy Platform, Sparks Partnering Talks at BIO 2026 (Exec Edge)
Jun-11-26 08:30AM	National AIDS Memorial and the Gilead Foundation Launch Major Investment to Expand HIV/AIDS Education and Community Leadership (Business Wire)
Jun-09-26 08:21AM	Merck, Gilead report mixed outcomes in key lung cancer, HIV studies (BioPharma Dive)
Jun-08-26 04:35PM	Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment (Business Wire)
04:30PM	Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study (Business Wire)
Jun-04-26 08:08PM	Gilead, Merck, Eli Lilly Lead $106B Biopharma Takeover Wave In 2026 (Stocktwits)
04:15PM	Gilead Sciences and Lakefront Complete Acquisition of Ouro Medicines to Further Expand Inflammation Pipeline (Business Wire)
Jun-03-26 07:09AM	Gilead eyes PBC expansion for Livdelzi on positive one-year data (Clinical Trials Arena)
Jun-02-26 08:30AM	Gilead's Livdelzi (Seladelpar) Delivers Statistically Significant Composite ALP Normalization in Phase 3 IDEAL Trial in Primary Biliary Cholangitis (PBC) (Business Wire)
May-29-26 06:17AM	Allogene CEO to step down; Agios drug fails key test (BioPharma Dive)
May-28-26 06:47AM	FDA accelerated approval of Hepcludex significant milestone for US HDV market (Clinical Trials Arena)
May-27-26 02:00AM	Phase 3 ASSURE Interim Data: Majority of People in the Study with ALP 1-1.67xULN Achieved High and Sustained Composite ALP Normalization at 24 Months with Gilead's Livdelzi (Seladelpar) (Business Wire)
May-26-26 06:16AM	Astellas eyes more cost cuts; FDA panel to debate Moderna vaccine (BioPharma Dive)
May-22-26 03:08PM	GILD Stock Jumps After Winning Accelerated FDA Approval For HDV Treatment (Stocktwits)
02:00PM	FDA Grants Accelerated Approval to Gilead's Hepcludex (bulevirtide-gmod), the First and Only Approved Treatment for Chronic Hepatitis Delta Virus (HDV) (Business Wire)
07:47AM	Gilead Receives CHMP Positive Opinion for Trodelvy in First-Line Metastatic Triple-Negative Breast Cancer for Patients Not Candidates for PD-(L)1 Inhibitors (Business Wire)
07:19AM	Gilead Sciences completes Tubulis acquisition for $5bn (Pharmaceutical Technology)
07:13AM	Gilead Sciences acquires Tubulis for $5bn (Pharmaceutical Business Review)
May-21-26 05:00PM	New ASCO and EHA 2026 Data Demonstrate Gilead and Kite's Momentum Across Antibody-Drug Conjugates and Cell Therapy in Oncology (Business Wire)
09:30AM	Gilead Sciences Completes Acquisition of Tubulis Further Strengthening Oncology Portfolio (Business Wire)
03:30AM	Gilead Sciences and World Health Organization Expand Collaboration to Help Eliminate Visceral Leishmaniasis, a Fatal Parasitic Disease (Business Wire)
May-20-26 09:43AM	Cigna downgraded, Humana upgraded: Wall Street's top analyst calls (The Fly)
May-18-26 08:35AM	Compugen surges after revenue tops forecasts despite quarterly loss miss (CGEN) (InvestorsHub)
May-14-26 09:21PM	Gilead Prices $3 Billion of Senior Unsecured Notes (Business Wire)
May-13-26 08:30AM	Gilead to Present New Data Advancing Care in PBC and Viral Hepatitis at EASL 2026 (Business Wire)
May-11-26 01:17PM	Here's how much Moderna's stock has rallied off renewed focus on hantavirus research (MarketWatch)
May-08-26 12:59PM	Gilead posts positive Q1 buoyed by HIV drug growth (Pharmaceutical Technology)
May-07-26 04:51PM	Gilead Earnings Show HIV Drugs Continue to Shine. Why the Guidance Cut? (Barrons.com)
04:39PM	Gilead Sciences Expects Loss This Year on Acquired R&D Expenses (The Wall Street Journal)
04:09PM	Gilead: Q1 Earnings Snapshot (Associated Press)
04:09PM	Gilead Tumbles On Mixed Guidance Update Amid Recent M&A Frenzy (Investor's Business Daily)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Dickinson Andrew D	Chief Financial Officer	Oct 15 '26	Sale	156.22	3,000	468,660	161,096	Oct 16 04:17 PM
Mercier Johanna	Chief Comm & Corp Aff Officer	Oct 15 '26	Sale	156.22	3,000	468,660	113,684	Oct 16 04:12 PM
JOHANNA MERCIER	Officer	Oct 15 '26	Proposed Sale	156.22	3,000	468,660		Oct 15 04:22 PM
ANDREW DICKINSON	Officer	Oct 15 '26	Proposed Sale	156.22	3,000	468,660		Oct 15 04:21 PM
O'Day Daniel Patrick	Chairman & CEO	Oct 01 '26	Sale	147.90	15,000	2,218,508	566,683	Oct 02 04:40 PM
Dickinson Andrew D	Chief Financial Officer	Sep 15 '26	Sale	145.29	3,000	435,870	164,096	Sep 16 04:30 PM
Mercier Johanna	Chief Comm & Corp Aff Officer	Sep 15 '26	Sale	144.22	3,000	432,646	116,684	Sep 16 04:27 PM
JOHANNA MERCIER	Officer	Sep 15 '26	Proposed Sale	144.22	3,000	432,646		Sep 15 04:20 PM
ANDREW DICKINSON	Officer	Sep 15 '26	Proposed Sale	145.29	3,000	435,870		Sep 15 04:04 PM
O'Day Daniel Patrick	Chairman & CEO	Sep 01 '26	Sale	148.64	15,000	2,229,592	577,133	Sep 02 04:12 PM
WELTERS ANTHONY	Director	Aug 26 '26	Option Exercise	61.06	18,000	1,099,052	23,176	Aug 27 06:44 PM
WELTERS ANTHONY	Director	Aug 26 '26	Sale	148.62	18,000	2,675,220	12,894	Aug 27 06:44 PM
ANTHONY WELTERS	Director	Aug 26 '26	Proposed Sale	148.77	18,000	2,677,860		Aug 26 04:16 PM
Bluestone Jeffrey	Director	Aug 20 '26	Option Exercise	67.04	5,000	335,207	11,882	Aug 21 07:22 PM
Bluestone Jeffrey	Director	Aug 20 '26	Sale	145.02	5,000	725,078	10,066	Aug 21 07:22 PM
JEFFREY BLUESTONE	Director	Aug 20 '26	Proposed Sale	147.60	5,000	738,000		Aug 20 04:36 PM
Dickinson Andrew D	Chief Financial Officer	Aug 17 '26	Sale	138.36	3,000	415,080	165,646	Aug 18 07:06 PM
Mercier Johanna	Chief Comm & Corp Aff Officer	Aug 17 '26	Option Exercise	67.07	25,000	1,676,773	146,234	Aug 18 06:54 PM
Mercier Johanna	Chief Comm & Corp Aff Officer	Aug 17 '26	Sale	137.64	28,000	3,853,908	118,234	Aug 18 06:54 PM
JOHANNA MERCIER	Officer	Aug 17 '26	Proposed Sale	137.64	28,000	3,853,908		Aug 17 04:18 PM
ANDREW DICKINSON	Officer	Aug 17 '26	Proposed Sale	138.36	3,000	415,080		Aug 17 04:11 PM
O'Day Daniel Patrick	Chairman & CEO	Aug 03 '26	Sale	130.31	15,000	1,954,694	592,133	Aug 04 05:40 PM
DANIEL O'DAY	Director	Aug 03 '26	Proposed Sale	130.21	55,000	7,161,550		Aug 03 04:41 PM
Dickinson Andrew D	Chief Financial Officer	Jul 15 '26	Sale	129.93	3,000	389,777	168,646	Jul 16 06:08 PM
Mercier Johanna	Chief Comm & Corp Aff Officer	Jul 15 '26	Sale	129.92	3,000	389,758	121,234	Jul 16 04:54 PM
JOHANNA MERCIER	Officer	Jul 15 '26	Proposed Sale	129.92	3,000	389,758		Jul 15 04:13 PM
ANDREW DICKINSON	Officer	Jul 15 '26	Proposed Sale	129.93	3,000	389,777		Jul 15 04:10 PM
O'Day Daniel Patrick	Chairman & CEO	Jul 01 '26	Sale	126.29	15,000	1,894,400	607,133	Jul 02 04:14 PM
Mercier Johanna	Chief Comm & Corp Aff Officer	Jun 15 '26	Sale	123.92	3,000	371,762	124,234	Jun 16 06:02 PM
Dickinson Andrew D	Chief Financial Officer	Jun 15 '26	Sale	125.40	3,000	376,200	171,646	Jun 16 05:53 PM
ANDREW DICKINSON	Officer	Jun 15 '26	Proposed Sale	125.40	3,000	376,200		Jun 15 04:30 PM
JOHANNA MERCIER	Officer	Jun 15 '26	Proposed Sale	123.92	3,000	371,762		Jun 15 04:09 PM
O'Day Daniel Patrick	Chairman & CEO	Jun 01 '26	Sale	131.46	15,000	1,971,847	617,567	Jun 02 06:04 PM
DANIEL O'DAY	Director	Jun 01 '26	Proposed Sale	134.43	35,000	4,705,050		Jun 01 04:45 PM
Dickinson Andrew D	Chief Financial Officer	May 15 '26	Sale	132.27	3,000	396,810	173,191	May 18 05:50 PM
Mercier Johanna	Chief Comm & Corp Aff Officer	May 15 '26	Option Exercise	66.64	25,000	1,666,000	153,779	May 18 05:45 PM
Mercier Johanna	Chief Comm & Corp Aff Officer	May 15 '26	Sale	131.29	28,000	3,676,199	125,779	May 18 05:45 PM
JOHANNA MERCIER	Officer	May 15 '26	Proposed Sale	131.29	28,000	3,676,198		May 15 04:09 PM
ANDREW DICKINSON	Officer	May 15 '26	Proposed Sale	132.27	3,000	396,810		May 15 04:07 PM
O'Day Daniel Patrick	Chairman & CEO	Apr 28 '26	Sale	129.16	10,000	1,291,608	632,567	Apr 29 05:53 PM
DANIEL O'DAY	Officer	Apr 28 '26	Proposed Sale	129.16	10,000	1,291,609		Apr 28 04:12 PM
Dickinson Andrew D	Chief Financial Officer	Apr 15 '26	Sale	140.96	3,000	422,880	176,191	Apr 16 06:41 PM
Mercier Johanna	Chief Comm & Corp Aff Officer	Apr 15 '26	Sale	140.96	3,000	422,880	128,779	Apr 16 06:40 PM
JOHANNA MERCIER	Officer	Apr 15 '26	Proposed Sale	140.96	3,000	422,880		Apr 15 04:12 PM
ANDREW DICKINSON	Officer	Apr 15 '26	Proposed Sale	140.96	3,000	422,880		Apr 15 04:08 PM
O'Day Daniel Patrick	Chairman & CEO	Mar 27 '26	Sale	136.82	10,000	1,368,162	642,567	Mar 30 05:59 PM
DANIEL O'DAY	Officer	Mar 27 '26	Proposed Sale	136.82	10,000	1,368,162		Mar 27 04:03 PM
Mercier Johanna	Chief Comm & Corp Aff Officer	Mar 16 '26	Sale	144.23	3,000	432,690	131,779	Mar 17 06:56 PM
Dickinson Andrew D	Chief Financial Officer	Mar 16 '26	Sale	144.23	3,000	432,690	179,191	Mar 17 06:14 PM
JOHANNA MERCIER	Officer	Mar 16 '26	Proposed Sale	144.23	3,000	432,690		Mar 16 04:06 PM
ANDREW DICKINSON	Officer	Mar 16 '26	Proposed Sale	144.23	3,000	432,690		Mar 16 04:06 PM
O'Day Daniel Patrick	Chairman & CEO	Feb 27 '26	Sale	144.79	10,000	1,447,859	642,308	Mar 02 04:46 PM
DANIEL O'DAY	Officer	Feb 27 '26	Proposed Sale	144.79	10,000	1,447,859		Feb 27 04:10 PM
Mercier Johanna	Chief Comm & Corp Aff Officer	Feb 17 '26	Option Exercise	66.64	25,000	1,666,000	148,288	Feb 18 05:22 PM
Mercier Johanna	Chief Comm & Corp Aff Officer	Feb 17 '26	Sale	154.44	28,000	4,324,228	120,288	Feb 18 05:22 PM
Dickinson Andrew D	Chief Financial Officer	Feb 17 '26	Sale	154.43	3,000	463,290	167,779	Feb 18 05:11 PM
JOHANNA MERCIER	Officer	Feb 17 '26	Proposed Sale	154.44	28,000	4,324,228		Feb 17 04:07 PM
ANDREW DICKINSON	Officer	Feb 17 '26	Proposed Sale	154.43	3,000	463,290		Feb 17 04:05 PM
O'Day Daniel Patrick	Chairman & CEO	Feb 05 '26	Option Exercise	66.01	115,640	7,633,396	729,552	Feb 06 04:22 PM
O'Day Daniel Patrick	Chairman & CEO	Feb 05 '26	Sale	150.00	115,640	17,346,000	613,912	Feb 06 04:22 PM
DANIEL O'DAY	Officer	Feb 05 '26	Proposed Sale	150.00	115,640	17,346,000		Feb 05 04:05 PM
O'Day Daniel Patrick	Chairman & CEO	Jan 28 '26	Sale	139.89	10,000	1,398,911	556,698	Jan 29 05:23 PM
DANIEL O'DAY	Officer	Jan 28 '26	Proposed Sale	139.89	10,000	1,398,911		Jan 28 05:02 PM
O'Day Daniel Patrick	Chairman & CEO	Jan 23 '26	Option Exercise	66.01	115,640	7,633,396	682,338	Jan 26 07:29 PM
O'Day Daniel Patrick	Chairman & CEO	Jan 23 '26	Sale	135.00	115,640	15,611,400	566,698	Jan 26 07:29 PM
DANIEL O'DAY	Officer	Jan 23 '26	Proposed Sale	135.00	115,640	15,611,400		Jan 23 04:03 PM
DEBORAH TELMAN	Officer	Jan 22 '26	Proposed Sale	129.11	29,215	3,771,949		Jan 22 04:32 PM
Bluestone Jeffrey	Director	Jan 20 '26	Option Exercise	67.45	5,000	337,250	13,920	Jan 21 04:26 PM
Bluestone Jeffrey	Director	Jan 20 '26	Sale	123.50	5,000	617,500	8,920	Jan 21 04:26 PM
JEFFREY BLUESTONE	Director	Jan 20 '26	Proposed Sale	123.50	5,000	617,500		Jan 20 04:01 PM
Dickinson Andrew D	Chief Financial Officer	Jan 15 '26	Sale	124.31	3,000	372,930	150,503	Jan 16 06:18 PM
Mercier Johanna	Chief Commercial Officer	Jan 15 '26	Sale	124.31	3,000	372,930	103,221	Jan 16 06:10 PM
JOHANNA MERCIER	Officer	Jan 15 '26	Proposed Sale	124.31	3,000	372,930		Jan 15 04:02 PM
ANDREW DICKINSON	Officer	Jan 15 '26	Proposed Sale	124.31	3,000	372,930		Jan 15 04:01 PM
O'Day Daniel Patrick	Chairman & CEO	Dec 29 '25	Sale	124.83	10,000	1,248,272	566,698	Dec 30 04:23 PM
DANIEL O'DAY	Officer	Dec 29 '25	Proposed Sale	124.83	10,000	1,248,272		Dec 29 04:04 PM
Dickinson Andrew D	Chief Financial Officer	Dec 15 '25	Sale	122.00	3,000	366,000	153,503	Dec 16 06:31 PM
Mercier Johanna	Chief Commercial Officer	Dec 15 '25	Sale	122.00	3,000	366,000	106,221	Dec 16 06:12 PM
JOHANNA MERCIER	Officer	Dec 15 '25	Proposed Sale	122.00	3,000	366,000		Dec 15 04:04 PM
ANDREW DICKINSON	Officer	Dec 15 '25	Proposed Sale	122.00	3,000	366,000		Dec 15 04:04 PM
Bluestone Jeffrey	Director	Nov 28 '25	Option Exercise	64.92	5,000	324,600	13,920	Dec 01 06:11 PM
Bluestone Jeffrey	Director	Nov 28 '25	Sale	125.08	5,000	625,400	8,920	Dec 01 06:11 PM
Kramer Kelly A.	Director	Nov 26 '25	Option Exercise	81.00	2,806	227,286	4,145	Dec 01 04:54 PM
Kramer Kelly A.	Director	Nov 28 '25	Option Exercise	81.00	2,805	227,205	4,144	Dec 01 04:54 PM
Kramer Kelly A.	Director	Nov 26 '25	Sale	127.11	2,806	356,671	1,339	Dec 01 04:54 PM
Kramer Kelly A.	Director	Nov 28 '25	Sale	127.10	2,805	356,516	1,339	Dec 01 04:54 PM
O'Day Daniel Patrick	Chairman & CEO	Nov 28 '25	Sale	126.54	10,000	1,265,444	571,203	Dec 01 04:50 PM
DANIEL O'DAY	Officer	Nov 28 '25	Proposed Sale	126.54	10,000	1,265,444		Nov 28 01:05 PM
JEFFREY BLUESTONE	Director	Nov 28 '25	Proposed Sale	125.08	5,000	625,400		Nov 28 01:02 PM
KELLY KRAMER	Director	Nov 26 '25	Proposed Sale	127.12	5,611	713,270		Nov 26 04:16 PM
Dickinson Andrew D	Chief Financial Officer	Nov 17 '25	Sale	125.23	2,500	313,075	154,555	Nov 18 07:00 PM
Mercier Johanna	Chief Commercial Officer	Nov 17 '25	Option Exercise	66.64	25,000	1,666,000	135,193	Nov 18 06:51 PM
Mercier Johanna	Chief Commercial Officer	Nov 17 '25	Sale	125.86	28,000	3,524,173	107,193	Nov 18 06:51 PM
JOHANNA MERCIER	Officer	Nov 17 '25	Proposed Sale	125.86	28,000	3,524,173		Nov 17 04:06 PM
ANDREW DICKINSON	Officer	Nov 17 '25	Proposed Sale	125.23	2,500	313,075		Nov 17 04:05 PM
Telman Deborah H	EVP, Corporate Affairs & GC	Nov 12 '25	Option Exercise	65.35	53,646	3,505,885	79,641	Nov 13 07:36 PM
Telman Deborah H	EVP, Corporate Affairs & GC	Nov 12 '25	Sale	122.85	53,646	6,590,487	43,676	Nov 13 07:36 PM
DIANE E WILFONG	Officer	Nov 13 '25	Proposed Sale	127.02	3,500	444,556		Nov 13 05:07 PM
DEBORAH TELMAN	Officer	Nov 12 '25	Proposed Sale	122.56	55,646	6,819,974		Nov 12 04:36 PM
O'Day Daniel Patrick	Chairman & CEO	Oct 28 '25	Sale	119.39	10,000	1,193,926	581,203	Oct 29 04:14 PM

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Chairman & CEOMr. Daniel Patrick O'Day

Executive VP & CFOMr. Andrew D. Dickinson

Chief Commercial & Corporate Affairs OfficerMs. Johanna Mercier

Ph.D.Dr. Dietmar P. Berger M.D.

Senior VPMs. Erin E. Burkhart

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Gilead Sciences Inc

Upgrade your Finviz experience